Bergapten alleviates osteoarthritis by regulating the ANP 32A/ ATM signaling pathway

Osteoarthritis ( OA ) is a chronic degenerative disease that commonly affects the elderly. Current drug therapies for treating OA may cause adverse side effects, and so there remains a need to develop alternative treatments. Bergapten (BG) is a coumarin phytohormone that is widely found in fruits and has antioxidative and anti‐inflammatory effects. Here, we tested the hypothesis that BG may restrict the progression of OA by examining its effect on OA chondrocytes. We observed that BG significantly ameliorated interleukin (IL)‐1β‐induced expression of inflammatory cytokines and mediators, including interleukin 1 ( Il‐1 ), interleukin 6 ( Il‐6 ), tumor necrosis factor α ( Tnf‐α ), cyclooxygenase 2 ( Cox‐2 ) and matrix metalloproteinase 13 ( Mmp‐13 ), maintained chondrocyte phenotype, and promoted the secretion of cartilage‐specific extracellular matrix. We provide evidence that BG exerts its anti‐inflammatory effect by activating the ANP 32A/ ATM signaling pathway, which was recently verified to be associated with OA . In conclusion, these findings indicate that BG may be a potential candidate for treatment of OA .